Grundlagenforschung an neuroendokrinen Neoplasien

Das ENETS-Zentrum Marburg ist seit jeher Mittelpunkt für klinische, als auch für Grundlagenforschung. Es existieren zwei Arbeitsgruppen für "neuroendokrine Neoplasien (NEN)" in der Abteilung für Gastroenterologie sowie bei unseren Kollegen der Chirurgie. Neben einer engen Zusammenarbeit innerhalb dieser Arbeitsgruppen ist es uns wichtig interdisziplinär Projekte zu planen und zu verwirklichen. Dabei bestehen weitreichende Kollaborationen vorrangig zu den Instituten der Pathologie, Radiologie sowie Nuklearmedizin. Unsere Grundlagenforschung beschäftigt sich mit neuen Therapieansätzen für NEN, welche in-vitro (in der Zellkultur) und in-vivo (Mausexperimenten) untersucht werden. Zusätzlich besteht ein Schwerpunkt in der Erforschung neuer Marker, welche zum einen eine Aussage über den Krankheitsverlauf treffen können (Prognosemarker) und zum anderen die bestmögliche individuelle Therapie für jeden Patienten erlaubt (prädiktive Marker). Falls Sie mehr über unsere Grundlagenforschung erfahren möchten, sind wir gerne bereit dies mit Ihnen zu besprechen und stehen für weitere Fragen zur Verfügung.

    

Literatur

  • Reimer RP, Reimer P, Mahnken AH. Assessment of Therapy Response to Transarterial Radioembolization for Liver Metastases by Means of Post-treatment MRI-Based Texture Analysis. Cardiovasc Intervent Radiol. 2018 Jun 7. doi:10.1007/s00270-018-2004-2.

  • Endoscopic Ultrasound Features of Multiple Endocrine Neoplasia Type 1-Related versus Sporadic Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Study. Tamagno G, Scherer V, Caimo A, Bergmann SR, Kann PH. Digestion. 2018;98(2):112-118. doi: 10.1159/000487939. Epub 2018 Apr 26.

  • Overexpression of MicroRNA miR-7-5p Is a Potential Biomarker in Neuroendocrine Neoplasms of the Small Intestine. Heverhagen AE, Legrand N, Wagner V, Fendrich V, Bartsch DK, Slater EP. Neuroendocrinology. 2018;106(4):312-317. doi: 10.1159/000480121. Epub 2017 Aug 19.

  • Prognosis of sporadic resected small (?2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study. Sallinen VJ, Le Large TYS, Tieftrunk E, Galeev S, Kovalenko Z, Haugvik SP, Antila A, Franklin O, Martinez-Moneo E, Robinson SM, Panzuto F, Regenet N, Muffatti F, Partelli S, Wiese D, Ruszniewski P, Dousset B, Edwin B, Bartsch DK, Sauvanet A, Falconi M, Ceyhan GO, Gaujoux S; Pancreas 2000 research group. HPB (Oxford). 2018 Mar;20(3):251-259.

  • Preoperative Imaging Overestimates the Tumor Size in Pancreatic Neuroendocrine Neoplasms Associated with Multiple Endocrine Neoplasia Type 1. Polenta V, Slater EP, Kann PH, Albers MB, Manoharan J, Ramaswamy A, Mahnken AH, Bartsch DK. World J Surg. 2018 May;42(5):1440-1447.

  • Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Short-Term and Long-Term Outcomes. Belfiori G, Wiese D, Partelli S, Wächter S, Maurer E, Crippa S, Falconi M, Bartsch DK. World J Surg. 2018 Oct;42(10):3223-3230.

  • Chemoprevention with Enalapril and Aspirin in Men1(+/T) Knockout Mouse Model. Manoharan J, Fendrich V, Di Fazio P, Bollmann C, Roth S, Joos B, Mintziras I, Albers MB, Ramaswamy A, Bertolino P, Zhang CX, Slater EP, Bartsch DK, Lopez-Lopez CL. Neuroendocrinology. 2018;107(3):257-266.

  • Implementation of Current ENETS Guidelines for Surgery of Small (?2 cm) Pancreatic Neuroendocrine Neoplasms in the German Surgical Community: An Analysis of the Prospective DGAV StuDoQ|Pancreas Registry. Mintziras I, Keck T, Werner J, Fichtner-Feigl S, Wittel U, Senninger N, Vowinkel T, Köninger J, Anthuber M, Geißler B, Bartsch DK; StuDoQ|Pancreas study group of the German Society for General and Visceral Surgery (DGAV). World J Surg. 2018 Aug 10.

  • [Neuroendocrine Neoplasia within the German NET Registry]. Im Namen aller Teilnehmer/innen am Deutschen NET-Registers; Authors; Kollaboratoren:. Z Gastroenterol. 2018 Oct;56(10):1237-1246.

  • Therapeutic Targeting of Tumor-Associated Macrophages in Pancreatic Neuroendocrine Tumors. Krug S, Abbassi R, Griesmann H, Sipos B, Wiese D, Rexin P, Blank A, Perren A, Haybaeck J, Hüttelmaier S, Rinke A, Gress TM, Michl P. Int J Cancer. 2018 Apr 26.

  • Bone Metastases in Patients with Neuroendocrine Neoplasm: Frequency and Clinical, Therapeutic, and Prognostic Relevance. Scharf M, Petry V, Daniel H, Rinke A, Gress TM. Neuroendocrinology. 2018;106(1):30-37.

  • Merola E, Pavel ME, Panzuto F, Capurso G, Cicchese N, Rinke A, Gress TM, Iannicelli E, Prosperi D, Pizzichini P, Prasad V, Kump P, Lipp R, Partelli S, Falconi M, Wiedenmann B, Delle Fave G.: Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications. J Clin Endocrinol Metab. 2017 May 1;102(5):1486-1494. doi: 10.1210/jc.2016-3732.

  • Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, Müller HH, Arnold R; PROMID Study Group.:Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology. 2017;104(1):26-32. Epub 2016 Jan 6.

  • Panzuto F, Merola E, Pavel ME, Rinke A, Kump P, Partelli S, Rinzivillo M, Rodriguez-Laval V, Pape UF, Lipp R, Gress T, Wiedenmann B, Falconi M, Delle Fave G.: Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. Oncologist. 2017 Apr;22(4):409-415. doi: 10.1634/theoncologist.2016-0351. Epub 2017 Feb 23.

  • Pfützner A, Pfützner AH, Kann PH, Burgard G.: Clinical and Laboratory Evaluation of a New Specific Point-of-Care Test for Intact Proinsulin. J Diabetes Sci Technol. 2017 Mar;11(2):278-283.

  • Koenig A, Krug S, Mueller D, Barth PJ, Koenig U, Scharf M, Ellenrieder V, Michl P, Moll R, Homayunfar K, Kann PH, Stroebel P, Gress TM, Rinke A: Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms. PLoS One. 2017 Dec 12;12(12):e0188876.

  • Krug S, Boch M, Rexin P, Gress TM, Michl P, Rinke A: Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors. Anticancer Res. 2017 May;37(5):2491-2500.

  • Krug S, Boch M, Nimphius W, Gress TM, Michl P, Rinke A.: Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy. Pancreatology. 2017 Jan - Feb;17(1):139-145

  • Kann PH, Moll R, Bartsch D, Pfützner A, Forst T, Tamagno G, Goebel JN, Fourkiotis V, Bergmann SR, Collienne M. Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) in insulinomas: Indications and clinical relevance in a single investigator cohort of 47 patients. Endocrine. 2017 Apr;56(1):158-163. doi: 10.1007/s12020-016-1179-z. Epub 2016 Nov 30. PubMed PMID: 27905047.

  • Albers MB, Librizzi D, Lopez CL, Manoharan J, Apitzsch JC, Slater EP, Bollmann C, Kann PH, Bartsch DK. Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1. World J Surg. 2017 Jun;41(6):1521-1527. doi: 10.1007/s00268-017-3907-9. PubMed PMID: 28138732.

  • Sallinen VJ, Le Large TTY, Tieftrunk E, Galeev S, Kovalenko Z, Haugvik SP, Antila A, Franklin O, Martinez-Moneo E, Robinson SM, Panzuto F, Regenet N, Muffatti F, Partelli S, Wiese D, Ruszniewski P, Dousset B, Edwin B, Bartsch DK, Sauvanet A, Massimo F, Ceyhan GO, Gaujoux S; Pancreas 2000 research group. Prognosis of sporadic resected small (?2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study. HPB (Oxford). 2017 Oct 5. pii: S1365-182X(17)30939-5. doi: 10.1016/j.hpb.2017.08.034. [Epub ahead of print] PubMed PMID: 28988702.

  • Di Fazio P, Maass M, Roth S, Meyer C, Grups J, Rexin P, Bartsch DK, Kirschbaum A. Expression of hsa-let-7b-5p, hsa-let-7f-5p, and hsa-miR-222-3p and their putative targets HMGA2 and CDKN1B in typical and atypical carcinoid tumors of the lung. Tumour Biol. 2017 Oct;39(10):1010428317728417. doi: 10.1177/1010428317728417. PubMed PMID: 29017393.

  • Polenta V, Slater EP, Kann PH, Albers MB, Manoharan J, Ramaswamy A, Mahnken AH, Bartsch DK. Preoperative Imaging Overestimates the Tumor Size in Pancreatic Neuroendocrine Neoplasms Associated with Multiple Endocrine Neoplasia Type 1. World J Surg. 2017 Oct 26. doi: 10.1007/s00268-017-4317-8. [Epub ahead of print] PubMed PMID: 29075857.

  • Manoharan J, Raue F, Lopez CL, Albers MB, Bollmann C, Fendrich V, Slater EP, Bartsch DK. Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary? World J Surg. 2017 Aug;41(8):2026-2032. doi: 10.1007/s00268-017-3992-9. PubMed PMID: 28321559.

  • Heverhagen AE, Legrand N, Wagner V, Fendrich V, Bartsch DK, Slater EP.: Over-Expression of miRNA miR-7-5p is a Potential Biomarker in Neuroendocrine Neoplasia of the Small Intestine. Neuroendocrinology. 2017 Aug 19. doi: 10.1159/000480121.

  • Kann PH, Moll R, Bartsch D, Pfützner A, Forst T, Tamagno G, Goebel JN, Fourkiotis V, Bergmann SR, Collienne M.: Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) in insulinomas: Indications and clinical relevance in a single investigator cohort of 47 patients. Endocrine. 2017 Apr;56(1):158-163. doi: 10.1007/s12020-016-1179-z. Epub 2016 Nov 30.

  • Nieser M, Henopp T, Brix J, Stoß L, Sitek B, Naboulsi W, Anlauf M, Schlitter AM, Klöppel G, Gress T, Moll R, Bartsch DK, Heverhagen AE, Knoefel WT, Kaemmerer D, Haybaeck J, Fend F, Sperveslage J, Sipos B.: Loss of Chromosome 18 in Neuroendocrine Tumors of the Small Intestine: The Enigma Remains. Neuroendocrinology. 2017;104(3):302-312. doi: 10.1159/000446917. Epub 2016 May 25

  • Partelli S, Tamburrino D, Lopez C, Albers M, Milanetto AC, Pasquali C, Manzoni M, Toumpanakis C, Fusai G, Bartsch D, Falconi M.: Active Surveillance versus Surgery of Nonfunctioning Pancreatic Neuroendocrine Neoplasms ?2 cm in MEN1 Patients. Neuroendocrinology. 2016;103(6):779-86.

  • Kletting P, Kull T, Maaß C, Malik N, Luster M, Beer AJ, Glatting G.: Optimized Peptide Amount and Activity for ??Y-Labeled DOTATATE Therapy. J Nucl Med. 2016 Apr;57(4):503-8.

  • Bodei L, Modlin IM, Luster M, Forrer F, Cremonesi M, Hicks RJ, Ezziddin S, Kidd M, Chiti A. Myeloid neoplasms after chemotherapy and PRRT: myth and reality. Endocr Relat Cancer. 2016 Aug;23(8):C1-7

  • Bartsch DK, Albers MB, Lopez CL, Apitzsch JC, Walthers EM, Fink L, Fendrich V, Slater EP, Waldmann J, Anlauf M.: Bronchopulmonary Neuroendocrine Neoplasms and Their Precursor Lesions in Multiple Endocrine Neoplasia Type 1. Neuroendocrinology. 2016;103(3-4):240-7.

  • Wiese D, Kampe K, Waldmann J, Heverhagen AE, Bartsch DK, Fendrich V.: C-Reactive Protein as a New Prognostic Factor for Survival in Patients With Pancreatic Neuroendocrine Neoplasia. J Clin Endocrinol Metab. 2016 Mar;101(3):937-44

  • Lopez CL, Albers MB, Bollmann C, Manoharan J, Waldmann J, Fendrich V, Bartsch DK.: Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1. World J Surg. 2016 Jul;40(7):1729-36

  • Lahner H, Rinke A, Unger N, Poeppel TD, Kühl H, Lehmann N, Führer D.: Sunitinib Efficacy in Patients with Advanced pNET in Clinical Practice. Horm Metab Res. 2016 Sep;48(9):575-80

  • Mueller D, Krug S, Majumder M, Rinke A, Gress TM.: Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors. BMC Cancer. 2016 Aug 18;16:645.

  • C-Reactive Protein as a New Prognostic Factor for Survival in Patients With Pancreatic Neuroendocrine Neoplasia. Wiese D, Kampe K, Waldmann J, Heverhagen AE, Bartsch DK, Fendrich V. J Clin Endocrinol Metab. 2016 Mar;101(3):937-44. doi: 10.1210/jc.2015-3114. Epub 2015 Dec 17.

  • Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, Barriuso J, Pavel M, O'Toole D, Walter T; other Knowledge Network members. Endocr Relat Cancer. 2015 Aug;22(4):657-64.

  • Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification. Krug S, Boch M, Daniel H, Nimphius W, Müller D, Michl P, Rinke A, Gress TM. PLoS One. 2015 Dec 2;10(12):e0143822.

  • Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex. Geis C, Fendrich V, Rexin P, Di Fazio P, Bartsch DK, Ocker M, Quint K, Heverhagen AE. J Surg Res. 2015 Apr;194(2):388-93.

  • IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells. Münzberg C, Höhn K, Krndija D, Maaß U, Bartsch DK, Slater EP, Oswald F, Walther P, Seufferlein T, von Wichert G. J Cell Mol Med. 2015 May;19(5):948-59.

  • Frequency and clinical correlates of somatic Ying Yang 1 mutations in sporadic insulinomas. Lichtenauer UD, Di Dalmazi G, Slater EP, Wieland T, Kuebart A, Schmittfull A, Schwarzmayr T, Diener S, Wiese D, Thasler WE, Reincke M, Meitinger T, Schott M, Fassnacht M, Bartsch DK, Strom TM, Beuschlein F. J Clin Endocrinol Metab. 2015 May;100(5):E776-82.

  • Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases. Partelli S, Inama M, Rinke A, Begum N, Valente R, Fendrich V, Tamburrino D, Keck T, Caplin ME, Bartsch D, Thirlwell C, Fusai G, Falconi M. Neuroendocrinology. 2015;102(1-2):68-76.

  • CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms. Krug S, Kühnemuth B, Griesmann H, Neesse A, Mühlberg L, Boch M, Kortenhaus J, Fendrich V, Wiese D, Sipos B, Friemel J, Gress TM, Michl P. Endocr Relat Cancer. 2014;21(6):879-90

  • Pancreatic polypeptide-rich islets in the posterior portion of the pancreatic head--a tumor mimic in somatostatin receptor scintigraphy. Albers MB, Maurer E, Klöppel G, Bartsch DK. Pancreas. 2014 May;43(4):648-50.

  • Enalapril and ASS inhibit tumor growth in a transgenic mouse model of islet cell tumors. Fendrich V, Lopez CL, Manoharan J, Maschuw K, Wichmann S, Baier A, Holler JP, Ramaswamy A, Bartsch DK, Waldmann J. Endocr Relat Cancer. 2014 Oct;21(5):813-24.

  • Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain. Bartsch DK, Slater EP, Albers M, Knoop R, Chaloupka B, Lopez CL, Fendrich V, Kann PH, Waldmann J.J Clin Endocrinol Metab. 2014 Nov;99(11):E2387-91.

  • Well-differentiated neuroendocrine neoplasia: relapse-free survival and predictors of recurrence after curative intended resections. Dieckhoff P, Runkel H, Daniel H, Wiese D, Koenig A, Fendrich V, Bartsch DK, Moll R, Müller D, Arnold R, Gress T, Rinke A. Digestion. 2014;90(2):89-97

  • Lopez CL, Falconi M, Waldmann J, Boninsegna L, Fendrich V, Goretzki PK, Langer P, Kann PH, Partelli S, Bartsch DK. Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. Ann Surg. 2013 Feb; 257(2):308-14.

  • Fendrich V, Wiese D, Waldmann J, Lauth M, Heverhagen AE, Rehm J, Bartsch DK. Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms. Ann Surg. 2011 Nov;254(5):818-23; discussion 823.

© ENETS-Zentrums Marburg